CureVac and GSK Resolve mRNA Vaccine Patent Dispute With BioNTech and Pfizer
CureVac N.V. (NASDAQ: CVAC) announced on August 7, 2025, that it has reached an agreement...
CureVac
BioNTech in Deal to Acquire CureVac for $1.25B to Boost Cancer mRNA Therapies
Germany-based BioNTech SE (NASDAQ: BNTX) announced plans to acquire all outstanding shares of fellow German...